Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

Emily Singer

A View from Emily Singer

Walgreens Halts Plans to Sell Genetic Tests

The drugstore responds to new regulatory concerns over direct-to-consumer genetic testing.

  • May 13, 2010

Walgreens announced yesterday that it will delay plans to sell a number of consumer genetic tests, developed by Pathway Genomics, after learning of concerns from the Food and Drug Administration (FDA). The agency sent Pathway a letter on Monday questioning whether the tests could be sold without the agency’s approval.

“In light of the FDA contacting Pathway Genomics about its genetic test kit and anticipated ongoing discussions between the two parties, we’ve elected not to move forward with offering the Pathway product to our customers until we have further clarity on this matter,” said Walgreens spokesman Jim Cohn, the Washington Post reported.

According to the newspaper, Pathway said in a statement late Wednesday, “We respect and understand Walgreens’s decision and we are communicating with the FDA about the Pathway Genomics Insight collection kit. Pathway works very diligently to ensure that our business is compliant with all applicable regulations and guidelines.”

The developments highlight the lack of clarity over regulation of direct-to-consumer genetic diagnostics. Other companies have sold similar tests over the internet, so it’s unclear why the FDA chose to intervene in this case. For both Pathway and other companies, such as 23andMe, consumers collect saliva samples themselves, and then the tests results are revealed via a specialized website. The dust-up isn’t the first for the direct-to-consumer genetics industry though–previous regulatory concerns have come from states, notably California and New York, rather than federal agencies.

According to the Post:

An FDA official told The Post on Monday that the test required the agency’s authorization because it involved consumers collecting their own DNA. Company officials disputed that, saying the test was exempt from FDA oversight because the testing was being done at its own lab.

But in a letter to Pathway released by the agency late Wednesday, the FDA’s James L. Woods notified the company that the test “appears to meet the definition of a device” under federal law, therefore making it subject to the agency’s review.

Be there when AI pioneers take center stage at EmTech Digital 2019.

Register now
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to MIT Technology Review.
  • Print + All Access Digital {! insider.prices.print_digital !}* Best Value

    {! insider.display.menuOptionsLabel !}

    The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    6 bi-monthly issues of print + digital magazine

    10% discount to MIT Technology Review events

    Access to entire PDF magazine archive dating back to 1899

    Ad-free website experience

    The Download: newsletter delivery each weekday to your inbox

    The MIT Technology Review App

  • All Access Digital {! insider.prices.digital !}*

    {! insider.display.menuOptionsLabel !}

    The digital magazine, plus unlimited site access, our online archive, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    Digital magazine (6 bi-monthly issues)

    Access to entire PDF magazine archive dating back to 1899

    The Download: newsletter delivery each weekday to your inbox

  • Print Subscription {! insider.prices.print_only !}*

    {! insider.display.menuOptionsLabel !}

    Six print issues per year plus The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Print magazine (6 bi-monthly issues)

    The Download: newsletter delivery each weekday to your inbox

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.